Therapeutic effects of Gancao Xiexin Decoction on renal ischemia-reperfusion injury based on network pharmacology and experimental validation Authors: Hongfeng Jin, Hao Zhang, Xiaokang Zheng, Xuejia Yang, Binbin Li Published: 2025 ABSTRACT AbstractBackgroundRenal ischemia-reperfusion injury (IRI) is a common clinical condition that triggers a complex cascade of biological responses, including inflammation, oxidative stress, and apoptosis. These responses can lead to impaired renal function and acute kidney injury (AKI). Despite advancements in therapeutic agents, there is still a need for safe and effective drugs. In this study, we investigated the therapeutic effects and mechanisms of Gancao Xiexin Decoction (GCXXD), an herbal compound known for its anti-inflammatory, antioxidant, and immunomodulatory properties, in treating renal IRI.MethodsWe utilized network pharmacology to identify the intersection targets of the active ingredients in GCXXD and AKI. Cytoscape software was used to obtain core targets, and the String database was used to map the interaction network of these targets. GO and KEGG enrichment analyses were conducted to assess the biological functions and potential pathways involved. Molecular docking simulations were performed to examine the binding of the main active components of GCXXD to the key pathways. Validation experiments were conducted using an IRI mouse model and a hypoxia-reoxygenation-mediated HK2 injury model.ResultsA total of 11 core targets of GCXXD for the treatment of AKI were identified. GO and KEGG analyses revealed enrichment in biological functions related to oxidative stress, apoptosis, and the PI3K/AKT signaling pathway. Molecular docking results indicated strong binding affinity between the key active components (baicalein, ginsenoside Rh2, quercetin, and wogonin) of GCXXD and the PI3K/AKT pathway. In both in vivo and ex vivo experiments, GCXXD activated the PI3K/AKT pathway and ameliorated renal IRI.ConclusionThis study demonstrated that GCXXD effectively improved ischemia-reperfusion-induced renal injury primarily via activating the PI3K/AKT pathway. These findings provided a scientific basis for the clinical application of GCXXD and paved the way for the development of new drugs and therapeutic strategies.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12882-025-04696-x.Keywords: GCXXD, IRI, AKI, Network pharmacology, PI3K/AKT Introduction Acute kidney injury (AKI) is linked to high morbidity and mortality and continues to be a critical global health issue. Renal IRI, a phenomenon that often occurs when renal tissues experience ischemia and subsequently regain perfusion, exacerbating the existing injury, plays a very important role in surgical trauma and renal transplant rejection, and is closely related to the progression of acute kidney injury [1]. In recent years, there has been a growing interest in the development of safe and effective drugs for the treatment of kidney injury induced by ischemia-reperfusion. Empagliflozin, a well-known oral hypoglycemic agent, was reported to mitigate renal IRI [2]. Another study found that trans-cinnamaldehyde, a compound isolated from cinnamon bark, improved renal IRI by suppressing inflammation [3]. The pathogenesis of IRI nephropathy is complex and variable, involving oxidative stress, inflammatory response, cell death, microvascular dysfunction, and immune response [4–10], and there is currently a lack of safe and effective therapeutic agents [11]. GCXXD is a classical traditional Chinese medicine compound composed of several Chinese herbs, including Gan Cao (Glycyrrhiza uralensis), Gan Jiang (Zingiber officinale), Ban Xia (Pinellia), Huang Qin (Scutellaria baicalensis), Dang Shen (Codonopsis pilosula), Da Zao (Ziziphus jujuba), and Huang Lian (Coptis chinensis). Currently, it is widely used in the treatment of various ulcerative diseases and leucosis [12]. Research have shown that GCXXD exhibits pharmacological effects such as promoting wound healing, anti-inflammatory properties, and immunomodulation and significant therapeutic effects on conditions like ankylosing spondylitis and rheumatoid diseases [13]. Additionally, Li et al. discovered that GCXXD manifested no significant toxic effects on the heart, liver, spleen, lungs and kidneys of Sprague-Dawley rats during oral toxicity assessments, indicating a favorable safety profile [14]. Additionally, the main active components of GCXXD, Zingiber officinale and Scutellaria baicalensis, have been observed to antagonize kidney injury [15–18], it remains unclear whether the complete prescription of GCXXD itself confers a protective effect against ischemic kidney injury. Given its diverse active ingredients and broad range of actions, there is speculation that GCXXD may have a crucial role in protecting against renal damage. However, it is important to note that further research is necessary to determine whether GCXXD exhibits a protective effect on renal damage caused by ischemia and reperfusion. Network pharmacology, a systems biology-based approach, aligns perfectly with the holistic philosophy of Traditional Chinese Medicine (TCM). It constructs complex networks of “compound-target-pathway-disease” interactions to systematically uncover the therapeutic mechanisms of multi-herb formulations [19–21]. This strategy has been successfully applied to decipher the mechanisms of various TCM prescriptions in diverse disease models. In this study, network pharmacology, molecular docking, and in vivo and in vitro experiments were conducted to investigate the renoprotective effects and potential mechanisms of GCXXD in acute kidney injury. Materials and methods Acquisition of components and targets of GCXXD The active ingredients of GCXXD, including “licorice” (Glycyrrhiza glabra), “Scutellaria baicalensis” (Scutellaria baicalensis), “ginseng” (Panax ginseng), “Coptis chinensis” (Coptis chinensis), “dried ginger” (Zingiber officinale), “jujube” (Ziziphus jujuba), and “Pinellia ternate” (Pinellia ternata), were retrieved through Traditional Chinese Medicine Systems Pharmacology and Analysis Platform Database (TCMSP, https://tcmsp-e.com/tcmsp.php) based on the criteria of bioavailability (OB) exceeding 30% and drug likeness (DL) greater than 0.18. The complete list of active ingredients for GCXXD can be found in a paper by Zhang et al. [22] Subsequently, the target protein names were converted to their corresponding gene names utilizing the UniProt database (https://www.uniprot.org/). AKI-related target identification AKI-related targets were identified by searching the GeneCards database (relevance score ≥ 1) (https://www.genecards.org/) using “acute kidney injury”, as well as the OMIM database (https://www.omim.org/), PharmGKB database (https://www.pharmgkb.org/), TTD database (https://db.idrblab.net/ttd/), and DisGeNET database (https://www.disgenet.org/). By merging the obtained results from the five databases and removing duplicate values, AKI-related targets were obtained. Subsequently, the online tool Venny (https://bioinfogp.cnb.csic.es/tools/venny/) was manipulated to generate a Venn diagram illustrating the intersection of the targets related to the active ingredients of GCXXD with the AKI-related target. Mapping the active ingredient-target network and construction of PPI network for Chinese herbal medicines The shared targets of AKI and the active ingredients of GCXXD were imported into Cytoscape 3.9.1 software. A network diagram of “active ingredient-target intersection” was constructed to analyze the relationship between active ingredients of GCXXD and the common targets associated with AKI. Next, the STRING platform (https://cn.string-db.org/cgi/input.pl) was employed to build a PPI network for the intersection targets [23]. The species was set as “Homo sapiens,” and the protein interaction threshold was set to “Medium confidence” (0.400), with free proteins hidden. The results obtained were visualized using Cytoscape. The Cytoscape-CytoNCA plugin was utilized to calculate various centrality measures such as degree centrality (DC), betweenness centrality (BC), proximity centrality (CC), eigenvector centrality (EC), and local average centrality (LAC) for each node as Table S1 shown. The targets with values exceeding the median were selected as the core targets, and the PPI network graph was generated. Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses of core targets Using R packages “dose,” “clusterprofiler”, “ggplot2”, “circlize”and “pathview”, GO and KEGG were carried out for core targets, and the top 30 enrichments in terms of cellular components (CC), molecular functions (MF), and biological processes (BP) were visualized. Similarly, the top 30 KEGG pathways were selected to generate bubble and circle plots, and optimal pathway information was obtained from the KEGG website (https://www.kegg.jp/) with access to the KEGG license [24–26]. Molecular docking Furthermore, molecular docking techniques were employed to verify potential binding modes and affinities between the key active ingredients of GCXXD and the protein core targets [27]. The three-dimensional (3D) SDF structures of the small molecule drugs were downloaded from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) and subsequently converted into PDB format using OpenBabel-2.3.2 software. The core protein targets were retrieved from the RCSB Protein Data Bank (PDB) (https://www.rcsb.org/), and any water molecules and small molecule ligands were removed using PyMOL software to prepare the receptor proteins for docking. For further processing, AutoDockTools 1.5.7 was utilized for tasks including protein receptor preparation, hydrogenation, and structural modification of the small molecule ligands. During the protein preparation process, the total charges of PI3K, AKT1, AKT2, and AKT3 were calculated using the Gasteiger charge distribution method, yielding values of 1.9922, -7.0312, 5.9734, and 0.0008, respectively. The prepared files were saved in pdbqt format, which is suitable for AutoDock’s docking simulation. Docking simulations were then carried out by setting the appropriate docking parameters, including the grid box size and coordinates, which defined the docking space and target regions on the protein receptor. After performing the docking, the conformations with the lowest binding energies were selected as the most probable binding modes. These binding modes were saved and visualized using PyMOL software to analyze the interactions between the ligands and the target proteins in greater detail. In addition, the protein and ligand were selected using PyMOL, and their structures were saved as PDB and SDF files, respectively. These files were then uploaded to PROTEINS PLUS (https://proteins.plus/) to obtain 2D docking interaction diagrams. Animal experiments and determination of blood creatinine and urea nitrogen Male C57BL/6 mice (6–8 weeks) purchased from and raised in the Animal Experiment Center of The First Affiliated Hospital of Wenzhou Medical University were provided suitable temperature, standard chow, sterilized water, and 12 h light/dark cycle. All mice were randomly divided into four groups (6 mice per group), recorded as Control, GCXXD group, IRI model, and IRI model combined with GCXXD (IRI + GCXXD) group. The GCXXD group was administered 8.55 g/kg GCXXD, while the IRI + GCXXD group received 8.55 g/kg of GCXXD for 24 h following IRI based on the relevant literature [28], the control group received equivalent normal saline. The IRI mice model were induced by bilateral renal pedicle clamping for 30 min followed by release for reperfusion. Mice were euthanized by isoflurane gas anesthesia. To measure serum creatinine and blood urea nitrogen levels, mouse serum was collected and quantified with the Creatinine (Cr) / BUN Assay Kit purchased from Nanjing Jiancheng Bioengineering Institute Co., Ltd. The raw data for serum creatinine can be found in Table S2. Hematoxylin-eosin (HE) and immunohistochemical (IHC) staining Renal tissue samples were first deparaffinized by immersing them in xylene and rehydrated through a graded series of ethanol solutions (100%, 95%, 85% and 70%) before being rinsed with distilled water. The tissues were then stained with Hematoxylin and Eosin (H&E) (Solarbio, China) following the standard protocol. Briefly, the tissues were stained with Hematoxylin for 5 min, followed by differentiation in 1% hydrochloric acid alcohol solution, and then counterstained with Eosin for 40 s. Neutral balsam was applied for mounting the samples. Images were captured under a Leica microscope. Additionally, IHC experiments were conducted to detect protein expression levels in kidneys as previously described [29]. Renal tissue sections (4 μm thickness) were fixed in 4% paraformaldehyde (Solarbio, China) for 48 h at room temperature, rinsed overnight, and then embedded in paraffin. After deparaffinization and hydration (through a graded ethanol series) as above, antigen retrieval was performed by heating the slides in a citrate buffer (Servicebio, China) in a microwave for 20 min. Following antigen retrieval, endogenous peroxidase activity was blocked by incubating the tissue sections with 3% hydrogen peroxide (BOSTER, USA) for 10 min. Non-specific binding was blocked by incubating the sections with goat serum (Boster, USA) for 30 min at room temperature. Subsequently, the tissue sections were incubated overnight at 4 °C with the following primary antibodies: anti-KIM-1 (1:200 dilution, Affinity, USA), anti-NGAL (1:200 dilution, Affinity, USA), anti-p-PI3K (1:100 dilution, Abcam, UK), and anti-p-AKT (1:100 dilution, Abcam, UK). After incubation, the sections were washed three times with PBS (Solarbio, China) and then incubated with HRP-conjugated secondary antibodies (Proteintech, China) (1:5000 dilution) at 37 °C for one hour. Finally, the immunoreactive proteins were visualized using DAB (Solarbio, China) staining for 2–5 min, and counterstaining was performed with hematoxylin (Solarbio, China). Samples were subsequently mounted with neutral balsam (Biosharp, China) for Leica microscopic analysis. Western blot Total proteins from kidney tissue and renal tubular epithelial cells (HK2) were extracted using RIPA lysate (Beyotime, China). The protein concentration was determined using the BCA kit (Beyotime, China) and were formulated to 20–40 µg using 5X loading buffer (BOSTER, USA). Subsequently, the proteins were separated by SDS-PAGE gel electrophoresis and transferred to PVDF membranes (Millipore, USA). The membranes were then blocked with 5% skimmed milk powder and incubated with primary antibodies including anti-KIM-1 (Affinity, USA), anti-NGAL (Affinity, USA), anti-GAPDH (Affinity, USA), anti-PI3K (Tyr607, Affinity, USA), anti-p-PI3K (Abcam, UK), anti-AKT (Abcam, UK), and anti-p-AKT (Tyr308, Abcam, UK) overnight at 4 °C. Following this, the membranes were washed and probed with secondary antibodies. The signals from the membranes were detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, USA). The full, unprobed membranes (Ponceau or Coomassie-stained) for the Western blot analyses have been provided as Fig. S1, and the corresponding raw blot images are included in the Supplementary File. Cell culture and CCK8 assay HK2 cells, sourced from the Cell Bank of the Chinese Academy of Sciences in Shanghai, China, were cultured in DMEM/F12 (Gibco, USA) supplemented with 10% FBS (Gibco, USA) and 1% penicillin-streptomycin (Invitrogen, USA). The cells were seeded uniformly in 96-well plates at a density of 5000 cells per well and treated with different concentrations of GCXXD for 24 h. To assess cell viability, the old medium was replaced with 100 µl of fresh medium and 10 µl of CCK8 reagent (Glpbio, USA) at 1, 2, and 3 h post-treatment. Then, absorbance values were measured, and cell viability was calculated using Prism 9.0 software. Subsequently, the HK2 cells were subjected to a 12-hour period of anaerobic incubation followed by 12 h of incubation in a CO2 incubator to simulate hypoxia-reoxygenation (HR)-induced renal injury in vitro. For the experimental treatments, the cells were exposed to 5 mg/ml of GCXXD, HR conditions, and combined treatment of 4 mg/ml GCXXD with HR simultaneously. The control group remained untreated. After 24 h, cell viability was assessed using the CCK8 reagent as described earlier. Immunofluorescence The cultured cells were rinsed thrice with PBS and then fixed using 4% paraformaldehyde for 15 min. Subsequently, they were permeabilized with 0.5% Triton X-100 and incubated overnight at 4 °C with the primary antibody anti-KIM-1 (Affinity, USA). Following this, the cells were treated with secondary antibodies conjugated with Alexa Fluor 594 for 1 h in the dark (Invitrogen, USA). Nuclei were counterstained with DAPI solution. The samples were ultimately photographed using a Leica microscope. Statistical analysis All data analyses were performed using Prism 9.0. Experiments were independently repeated three times. For numerical variables that followed a normal distribution, one-way analysis of variance (ANOVA) was used to analyze differences among multiple groups. A p-value of less than 0.05 was considered statistically significant. Results Prediction of the target of action of GCXXD for AKI treatment A total of 1602 AKI-related targets were obtained after screening through GeneCards, the OMIM database, PharmGKB, TTD, and the DisGeNET database (Fig. 1A, B). Additionally, 242 GCXXD component targets were identified using the TCMSP database. By comparing the drug component targets with the AKI-related targets, 117 intersecting targets were identified, which represent the relevant targets of GCXXD for AKI treatment (Fig. 1C). Predictions of common targets of GCXXD for the treatment of AKI. (A) Venn diagram (B) histogram illustrating the AKI-associated shared targets across five databases. (C) Venn diagram depicting the overlap of drug-disease common targets between the active ingredient target genes in GCXXD and AKI-related genes Network diagram of active ingredient of GCXXD-target protein-disease and core target screening To visualize the specific targets of GCXXD for the treatment of AKI, a network diagram illustrating the active ingredients, target proteins, and diseases of the Chinese medicine was generated using Cytoscape 3.9.1 software (Fig. 2). In the Figure, the colored circles represent the various active ingredients of the drug, the blue rectangles indicate the 117 intersecting targets of the drug-disease, and the connecting lines depict the interactions between the drug ingredients and the disease targets. The complex connections observed suggest that GCXXD is rich in multiple active ingredients and possesses a broad spectrum of therapeutic effects, allowing it to act on multiple targets simultaneously. Utilizing the String platform, an interaction network of 117 common targets between GCXXD and AKI-related proteins was obtained (Fig. 3A). By using the Cytoscape-CytoNCA plug-in to compute the top 20 genes for DC, BC, CC, EC, and LAC, we filtered out 11 core targets, namely AKT1, HIF1A, TP53, MMP9, STAT3, CXCL8, PTGS2, EGFR, IL1B, MYC, and BCL2 (Fig. 3B-D). Target network of GCXXD active ingredients PPI network diagrams of common and core targets. (A) PPI network of common targets in the String database. (B) PPI network of common targets plotted by Cytoscape. (C) Venn diagram illustrating core target screening. (D) PPI network of core targets generated by the String database GO functional enrichment and KEGG pathway analysis GO analysis of the core targets identified significant enrichment in 189 biological processes, 77 cellular components, and 92 molecular functions, with key functions related to DNA-binding transcription factor binding, membrane microdomain, and responses to xenobiotic stimulus (Fig. 4A, B). KEGG analysis revealed 458 pathways, with the top 30 involving PI3K-AKT signaling, lipid and atherosclerosis, AGE-RAGE signaling, and TNF signaling (Fig. 4C, D). The PI3K-AKT signaling pathway emerged as a promising regulatory pathway for GCXXD in the treatment of AKI due to its strong correlation with the core targets. (Fig. 5). GO and KEGG enrichment analyses of core targets. Histogram (A) and circular plot (B) for GO enrichment analysis. Bubble plot (C) and circular plot (D) for KEGG enrichment analysis. For the circular plots, the outermost circle displays the number of GO terms or KEGG numbers. The second circle indicates the total number of targets, with darker red shades denoting higher significance. The third circle represents core targets, while the fourth circle depicts the enrichment factor, calculated as the number of targets involved in a pathway divided by the total number in that pathway. Enrichment factors range from 0 to1, transitioning in the gray area from inner to outer circles The PI3K-AKT signaling pathway, where red and green colors represent up-regulated and down-regulated proteins, respectively Molecular docking validates the binding of GCXXD to receptor proteins Autodock 1.5.7 software was used to confirm the molecular docking of four key active ingredients in GCXXD, namely baicalein, ginsenoside Rh2, quercetin, and wogonin, with PI3K/AKT. It is commonly accepted that a higher absolute value of binding energy indicates tighter binding between the target gene and the active ingredient. A binding energy below − 17.78 kJ/mol suggests that the small-molecule ligand exhibits certain binding activity to the receptor, while a value below − 20.92 kJ/mol (-5.0 kcal/mol) indicates better binding activity, and below − 29.29 kJ/mol demonstrates strong binding activity [30]. The results revealed that receptor proteins PI3K and AKT1/2/3, along with their associated active components baicalein, ginsenoside Rh2, quercetin, and wogonin were all able to bind. There were better binding affinities between PI3K with wogonin, AKT1 with baicalein, ginsenoside Rh2, quercetin, and wogonin, AKT2 with baicalein and wogonin, AKT3 with baicalein, quercetin (Fig. 6A, B). The molecular docking results revealed that several active components of GCXXD, such as quercetin and ginsenoside Rh2, exhibited strong binding affinities with core targets in the PI3K/AKT pathway. This multi-component, multi-target characteristic is a hallmark of TCM formula action, suggesting that the therapeutic effect of GCXXD is likely achieved through the synergistic modulation of the PI3K/AKT pathway by its various bioactive constituents, rather than through a single highly specific ligand-receptor interaction. Docking analysis of the main active components of GCXXD with PI3K/AKT. (A) The table shows the binding affinities of the main active components of GCXXD with PI3K/AKT. The unit of the values is kcal/mol. (B) Autodock schematic of the main active ingredients of GCXXD interacting with PI3K/AKT GCXXD ameliorates renal injury in vitro and in vivo experiments Compared to the model group, the GCXXD-treated group exhibited a significant decrease in blood creatinine and urea nitrogen concentrations, although they did not return to normal levels. However, the administration of GCXXD alone did not have any impact on the release of blood creatinine and urea nitrogen when compared to the control group (Fig. 7A). Western blot results demonstrated that GCXXD treatment effectively attenuated renal injury markers KIM-1 and NGAL (Fig. 7B). Strikingly, histopathological analysis revealed that GCXXD alleviated tubular dilatation, inflammatory cell infiltration, and tubular epithelial brush border detachment observed in the model group (Fig. 7C). Immunohistochemical staining corroborated these findings. Given that renal tubular epithelial cells are highly susceptible to injury, HK2 cells were employed for in vitro studies. Cell viability showed no significant difference when exposed to GCXXD concentrations up to 4 mg/ml, while cell growth was inhibited under 5 mg/ml GCXXD treatment (Fig. 8A). Additionally, GCXXD ameliorated HR-induced cell injury at the concentration of 4 mg/ml (Fig. 8B-D). These results collectively indicate the nephroprotective effects of GCXXD both in vivo and ex vivo. GCXXD alleviates renal injury induced by IRI. (A) Blood creatinine concentrations in each group. (B) Urea nitrogen concentrations in each group. (C) Western blot analysis of KIM-1 and NGAL expression levels. Red, black, and green arrows indicate epithelial cell vacuolization, tubular dilatation, and epithelial cell detachment, respectively. (D) Immunohistochemical staining showing the expression levels of KIM-1 and NGAL. ***p < 0.001, ****p < 0.0001 GCXXD attenuates HK2 cell injury induced by HR. (A) CCK8 assay depicting the effect of different concentrations of GCXXD on cell viability. (B) CCK8 assay demonstrating the protective effect of GCXXD against HR-induced cellular toxicity. (C) Protein expression of KIM-1 and NGAL. (D) Fluorescence intensity variations of KIM-1 upon exposure to different treatments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 GCXXD protects against ischemia and reperfusion or HR-mediated kidney injury by inhibiting the PI3K/AKT pathway Our KEGG analysis showed significant enrichment in the PI3K/AKT signaling pathway. Additionally, we found that the key active components of GCXXD exhibited better binding affinity with the proteins involved in this pathway. To further substantiate these findings, we conducted experiments to investigate the effect of GCXXD on the PI3K/AKT signaling pathway in renal IRI. Further research revealed that GCXXD antagonized renal injury by activating the PI3K/AKT signaling pathway. Our findings illustrated that phosphorylation of PI3K and AKT was significantly enhanced in the GCXXD-treated group compared to the IRI/HR group with no discernible difference in their total protein expression (Fig. 9A, B). Similarly, the levels of PI3K and AKT phosphorylation were observed to be restored to higher levels in the GCXXD-treated group of mice compared to the IRI mice (Fig. 9C, D). This study combines network pharmacology and experimental validation to illustrate that GCXXD exerts its antagonistic effect on AKI by inhibiting the PI3K/AKT pathway (Fig. 10). GCXXD abolishes the inhibition of the PI3K/AKT pathway by IRI/HR. (A) In vivo effects of GCXXD on the PI3K/AKT pathway. (B) In vitro effects of GCXXD on the PI3K/AKT pathway. (C) Effects of GCXXD on phosphorylated PI3K (p-PI3K). (D) Effects of GCXXD on phosphorylated AKT (p-AKT) The schematic diagram of this study Discussion Renal IRI is a common clinical condition resulting from multiple pathological factors and is a causative factor in AKI and renal failure [31]. In clinical practice, symptomatic treatments such as blood pressure control, rehydration, antioxidant use to mitigate the damage caused by reactive oxygen species to the kidneys, anti-inflammatory medications to lessen the inflammatory response, nutritional support, and renal replacement therapy like dialysis in severe cases, are commonly employed. Moreover, there is increasing evidence supporting the utilization of herbal remedies for intervening in ischemia and reperfusion-induced renal injury [32–34]. In general, multi-component and multi-targeted treatment is more effective than single-targeted treatment of diseases. Leveraging the advantages of Chinese medicine, which incorporates multi-pathway, multi-targeted, and comprehensive concepts along with evidence-based treatment, has proven highly effective. In modern clinical practice, GCXXD has demonstrated significant efficacy in conditions such as Behçet’s disease, ulcerative colitis, gastrointestinal ulcers, gynecological disorders, and eczema [13, 35, 36]. A recent study also discovered that GCXXD inhibited the growth of gastric cancer cells, promoted apoptosis and G0/G1 phase blockade, and reduced the number of clone formations, thereby restraining the proliferation and migration of gastric cancer [37]. However, the role of GCXXD in renal IRI and its mechanism of action remain unclear. Based on TCMSP database, 1605 GCXXD active ingredients were obtained in this study, mainly containing 7 active ingredients of “licorice,” “Scutellaria baicalensis,” “ginseng,” “Coptis chinensis,” “dried ginger,” “jujube,” and “Pinellia ternate”. Previous studies have shown that licorice pretreatment restored endogenous antioxidant enzymes peroxidase and glutathione peroxidase activities and improved renal function in ischemia-reperfusion rats [38]. Ginseng treatment alleviated renal structural and functional damage and reduced macrophage infiltration in mice post-IRI [39]. Scutellaria baicalensis improved renal function by upregulating phosphorylated AKT, decreasing levels of inflammatory cytokines like tumor necrosis factor-alpha, interleukin-1, interleukin-6, increasing the anti-apoptotic protein Bcl-2 levels, and decreasing the pro-apoptotic protein Bax levels in the kidney, thereby ameliorating renal injury induced by ischemia and reperfusion [40]. Coptis chinensis exerted a protective effect against renal IRI by counteracting oxidative stress and apoptosis [41]. Cytoscape 3.9.1 software was utilized to construct a network diagram depicting the drug-active ingredient-disease intersection targets. PPI network analysis identified 11 core targets, namely AKT1, HIF1A, TP53, MMP9, STAT3, CXCL8, PTGS2, EGFR, IL1B, MYC, and BCL2. AKT1 is a serine/threonine protein kinase that plays a crucial role in cellular growth and survival processes [42]. It has been shown that in AKT1-deficient mice, serum creatinine levels are elevated, apoptosis is increased, the expression of tumor necrosis factor-α/interleukin-6/interleukin-1β is upregulated, and kidney injury is exacerbated [43]. HIF1A, STAT3 and MYC were identified as potential biomarkers of renal IRI [44]. TP53 is one of the important oncogenes, regulating cell cycle, apoptosis, differentiation and metabolism [45]. Matrix metalloproteinase 9 (MMP9) can hydrolyse a variety of proteins and involve in tissue remodeling, angiogenesis, immune and inflammatory response [46]. Li et al. found that renal pathological injury was attenuated in IRI rats by decreasing the expression of TP53 and MMP9 [47]. A review of the relevant literature revealed that the inflammatory factor IL1B, chemokine ligand CXCL8, B-cell leukaemia/lymphoma 2 (BCL2), prostaglandin-endoperoxide synthase 2 (PTGS2) and epidermal growth factor receptor (EGFR) were associated with IRI [48–51]. Based on biological function analysis and pathway results, it is suggested that GCXXD may exert therapeutic effects on renal AKI through various mechanisms, such as the PI3K/AKT signaling pathway, immunomodulation, antioxidant damage, and anti-inflammatory effects. PI3K/AKT signaling pathway promotes cell survival and inhibits apoptosis by activating downstream effectors such as mTOR, Bad, and GSK-3β [52–56]. In the context of renal ischemia-reperfusion injury (IRI), this pathway aids renal tissue in coping with damage by reducing apoptosis, enhancing cell repair, and modulating oxidative stress responses. Specifically, PI3K/AKT activation inhibits the expression of pro-inflammatory cytokines, thereby attenuating the inflammatory response during IRI and reducing renal injury. Furthermore, PI3K/AKT signaling increases the expression of antioxidant enzymes, mitigating oxidative damage caused by reactive oxygen species (ROS) and alleviating cellular injury induced by IRI [53–55, 57]. Moreover, PI3K/AKT pathway plays a crucial role in endothelial cells. It not only promotes angiogenesis and enhances vascular permeability but also improves microcirculation, which helps restore renal blood flow and reduces the ischemic damage caused by insufficient perfusion [58]. These combined effects underscore the multifaceted protective role of PI3K/AKT signaling pathway in the repair of renal IRI, highlighting its significant potential for clinical application. Notably, our study produced consistent data. KEGG pathway analysis revealed that PI3K/AKT signaling pathway is the most enriched, and activation of this pathway by GCXXD effectively alleviated renal ischemia-reperfusion injury. Next, our molecular docking results indicated that the main active component of GCXXD exhibited significant binding affinity with PI3K/AKT signaling. Animal experiments further confirmed that GCXXD attenuated renal histopathological damage, improved renal function, and reduced the expression of kidney injury indicators (such as KIM-1 and NGAL) in renal IRI. Similar results were yielded from cellular experiments. Additionally, comprehensive studies have revealed that GCXXD primarily alleviates renal IRI by activating the PI3K/AKT pathway, which is consistent with previous analyses. However, there are certain limitations in this study. First, our research relies on existing databases and models, which to some extent overlook the complexity of systems biology, such as the spatiotemporal specificity of gene expression and the influence of environmental factors, potentially leading to the omission of important variables. Second, some novel drug targets or pathways may not have been discovered or recorded yet, meaning that the current models may fail to encompass all possible biological mechanisms. Third, the experimental validation relies on animal models to predict the effects of drugs in humans, which may introduce bias. Future studies will focus on identifying additional molecular targets through which GCXXD exerts its effects, as well as investigating the underlying mechanisms of each individual herbal compound in the treatment of renal IRI. Conclusion Taken together, the present study screened the potential core targets of GCXXD for treating renal IRI, including AKT1, HIF1A, TP53, MMP9, STAT3, CXCL8, PTGS2, EGFR, IL1B, MYC, and BCL2, and confirmed that GCXXD attenuated renal IRI by activating the PI3K/AKT signaling pathway, which provides an alternative and theoretical basis for the treatment of IRI. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1: Figure S1. The full, unprobed Ponceau/Coomassie-stained membrane for Western blot analyses. Supplementary Material 2: Figure S2. The quality control chromatogram of GCXXD33 [28]. Supplementary Material 3: Table S1. The degree centrality (DC), betweenness centrality (BC), closeness centrality (CC), eigenvector centrality (EC), and local average centrality (LAC) of the 117 shared genes. Supplementary Material 4: Table S2. Serum/plasma creatinine raw data. Supplementary Material 5 Acknowledgements We are very grateful to the members of the research team for their efforts in the experiment. Author contributions B.L. designed the study and provided fund support. H.J., H.Z. and X.Z. performed the experimental validation. X.Y. supervised the study and conducted the data analysis. Funding This work is supported by the fund Wenzhou Basic Public Welfare Research Project. (Grant ID: Y2023222). Data availability Data inquiries can be directed to the corresponding author. Declarations Ethical approval Animal experiments were conducted in accordance with the guidelines and regulations of the Animal Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and this animal study was approved by the Animal Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University under the approval number W. Y-AEC-2022-059. Consent to participate Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1: Figure S1. The full, unprobed Ponceau/Coomassie-stained membrane for Western blot analyses. Supplementary Material 2: Figure S2. The quality control chromatogram of GCXXD33 [28]. Supplementary Material 3: Table S1. The degree centrality (DC), betweenness centrality (BC), closeness centrality (CC), eigenvector centrality (EC), and local average centrality (LAC) of the 117 shared genes. Supplementary Material 4: Table S2. Serum/plasma creatinine raw data. Supplementary Material 5 Data Availability Statement Data inquiries can be directed to the corresponding author.